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The increasing use of single cell gel electrophoresis (the
comet assay) highlights its popularity as a method for de-
tecting DNA damage, including the use of enzymes for
assessment of oxidatively damaged DNA. However, compar-
ison of DNA damage levels between laboratories can be
difﬁcult due to differences in assay protocols (e.g. lysis con-
ditions, enzyme treatment, the duration of the alkaline treat-
m e n ta n de l e c t r o p h o r e s i s )a n di nt h ee n dp o i n t su s e df o r
reporting results (e.g. %DNA in tail, arbitrary units, tail
moment and tail length). One way to facilitate comparisons is
to convert primary comet assay end points to number of
lesions/10
6 bp by calibration with ionizing radiation. The aim
of this study was to investigate the inter-laboratory variation
in assessment of oxidatively damaged DNA by the comet
assay in terms of oxidized purines converted to strand breaks
with formamidopyrimidine DNA glycosylase (FPG). Coded
samples with DNA oxidation damage induced by treatment
with different concentrations of photosensitizer (Ro 19-8022)
plus light and calibration samples irradiated with ionizing
radiation were distributed to the 10 participating laborato-
ries to measure DNA damage using their own comet assay
protocols. Nine of 10 laboratories reported the same ranking
of the level of damage in the coded samples. The variation in
assessment of oxidatively damaged DNA was largely due to
differences in protocols. After conversion of the data to
lesions/10
6 bp using laboratory-speciﬁc calibration curves,
the variation between the laboratories was reduced. The
contribution of the concentration of photosensitizer to the
variation in net FPG-sensitive sites increased from 49 to
73%, whereas the inter-laboratory variation decreased. The
participating laboratories were successful in ﬁnding a dose–
response of oxidatively damaged DNA in coded samples, but
there remains a need to standardize the protocols to enable
direct comparisons between laboratories.
Introduction
Alkaline single cell gel electrophoresis (the comet assay) is a
method used to measure single strand breaks (SSB) and
alkali-labile sites (ALS). One reason for the increasing
interest in using the method is the low number of cells
required to measure DNA lesions. A range of different types
of DNA lesions can be measured by adding lesion-speciﬁc
enzymes (1). A common modiﬁcation of the assay is to
measure the level of 8-oxoguanine as well as other altered
p u r i n e sb yi n c o r p o r a t i n gad i g e s t i o nw i t ht h eb a c t e r i a lD N A
repair enzyme formamidopyrimidine DNA glycosylase (FPG)
(1). In addition, the comet assay can be modiﬁed to measure
DNA incision activity reﬂecting base excision repair (2) and
nucleotide excision repair (3). Several guidelines for the
comet assay have been published (4–7), but there are still
considerable differences in protocols used by different
research groups. These differences affect inter-laboratory
comparisons of results and there is no general agreement
about the normal background level of DNA lesions measured
by the comet assay. Important steps in the comet assay
procedure that may affect the variability are: (i) cell treatment/
dilution in agarose, (ii) duration of enzyme treatment, (iii)
duration and pH of alkaline treatment, (iv) electrophoresis
conditions and (v) slide scoring. In addition, the fact that
different laboratories use different end points (i.e. %DNA in
tail, tail moment, tail length and arbitrary units as well as
various descriptions of the distribution of images) when
reporting their results further complicates the comparison of
data between different laboratories. Møller et al. (8) have
previously shown that there is substantial variation when
different investigators score the same slides by visual
classiﬁcation of comets. Forchhammer et al. (9) recently
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could be reduced to a large extent by using investigator- and
protocol-speciﬁc calibration curves.
The aim of this study was to assess variation in estimates of
oxidatively damaged DNA, in terms of FPG-sensitive sites,
measured with the comet assay by 10 different European
Comet assay Validation Group (ECVAG) partners using their
own protocols when analyzing coded samples.
Materials and methods
Study design
In order to investigate the inter-laboratory variation in the analysis of oxidation
damage to DNA, 10 laboratories measured the level of DNA damage in four
c-ray irradiated calibration samples and three coded samples of human cells
using their own protocols. The three coded samples contained cells with dif-
ferent amounts of 8-oxoguanine in their DNA. Cryopreserved calibration curve
samples, coded samples and aliquots of FPG from the same batch were dis-
tributed on dry ice to the participating laboratories. Laboratories were instructed
to analyse the calibration samples together with the coded samples, in order to
create laboratory-speciﬁc calibration curves. Each laboratory completed a ques-
tionnaire on their comet assay protocol (Table I).
Reagents and enzymes
Trypsin–ethylenediaminetetraacetic acid (EDTA), Dulbecco’s Minimal Essen-
tial Medium (DMEM), Roswell Park Memorial Institute (RPMI) 1640 medium,
foetal bovine serum (FBS), penicillin–streptomycin and sodium pyruvate were
purchased from Invitrogen Corporation, Karlsruhe, Germany. FPG was
supplied by one of the participating laboratories (Department of Nutrition,
University of Oslo, Norway).
Preparation of calibration curve samples
Samples of human acute monocytic leukaemia THP1 cells in phosphate-
buffered saline (PBS) were irradiated with c-rays at 0, 2.5, 5 and 10 Gy as
described previously (9). Aliquots of cells were frozen slowly to  80C in 50%
FBS, 40% RPMI 1640 medium and 10% dimethyl sulfoxide (DMSO).
Preparation of coded samples with 8-oxoguanine
A549 human type II alveolar epithelial cells were cultured and harvested as
described previously (10). The cells were centrifuged at 400   g for 5 min at
4C; the cell pellet was suspended in PBS and centrifuged again. Cells were
divided into three portions and suspended in PBS or in PBS containing 0.2 or
0.8 lM of the photosensitizer Ro 19-8022. Treatment with photosensitizer Ro
19-8022 and visible light predominantly generates 8-oxoguanine (11). All three
cell suspensions were irradiated on ice for 5 min from a distance of 33 cm with
a 500-W tungsten halogen lamp. Following irradiation, cells were immediately
centrifuged (500   g) for 5 min at 4C. The cell pellets of the coded samples
were suspended in freezing medium consisting of 20% FBS, 70% DMEM and
10% DMSO, aliquoted and frozen slowly to  80C.
The comet assay
The 10 participating laboratories used their own comet assay protocols to
measure the level of FPG-sensitive sites. The basic procedure was common for
all laboratories. Cells were embedded in low-melting point agarose (for con-
centrations see Table I) and then lysed (1% Triton X-100, 2.5 M NaCl, 0.1 M
EDTA, 10 mM Tris, pH 10) for a minimum of 1 h at 4C. In addition, the lysis
solution of Laboratory 3 contained 1% DMSO and the lysis solution of
Laboratory 8 contained both 1% DMSO and 1% N-lauroylsarcosine sodium salt.
For the coded samples, an additional step of digestion with FPG was added in
order speciﬁcally to measure oxidative DNA lesions. FPG recognizes and
removes speciﬁc oxidatively damaged purines creating an apurinic site, leading
to a strand break either by the enzyme’s associated lyase activity or by the
subsequent alkaline treatment. After lysis, the gels were washed 3  in buffer
(40 mM HEPES, 0.1 M KCl, 0.5 mM EDTA, 0.2 mg/ml bovine serum albumin,
pH 7.8–8) and then incubated with buffer containing FPG. Enzyme incubation
was performed at 37C for between 10 and 45 min, depending on the laboratory
(Table I). Eight laboratories (1–3 and 5–9) incubated parallel gels in enzyme
buffer with and without FPG, thereby enabling estimation of background DNA
breaks and the calculation of net FPG-sensitive sites, whereas two laboratories
(4 and 10) only incubated gels with FPG. Slides were placed in an alkaline
solution (0.3 M NaOH, 1 mM EDTA, pH . 13) for 20–40 min (Table I),
followed by electrophoresis in the same solution for 20–30 min (Table I). By
their ability to relax DNA supercoiling, strand breaks allow DNA to migrate out
from the nucleoids under the inﬂuence of the electric ﬁeld. The DNA was
stained (Table I) and the comets, with tails of relaxed and mainly single-stranded
DNA, were analysed either by visual scoring or by computerized image analysis.
Different comet assay end points
The magnitude of the comet tail can be reported in different units e.g. %DNA in
tail, tail moment and tail length when using computerized scoring or arbitrary
units when using visual scoring. Some laboratories reported several end points.
Arbitrary units (from visual scoring) are normally reported in the range
0–400 (1). A direct comparison of the data obtained by computerized and visual
scoring can be obtained by dividing the visual score by a factor of 4, so that the
visual score has the same range as %DNA in tail (0–100), though this is only an
approximate equivalence. Since Laboratory 5 only reported results in arbitrary
units, its results have been transformed in this way and are referred to as
%DNA in tail.
Calculations of the amount of lesions/10
6 bp
One gray of c-rays induces 0.29-strand breaks/10
9 Da DNA [based on a mean
of the levels reported by Ahnstro ¨m et al. (12) and Kohn et al. (13)]. Based on
this dose equivalence and the assumption that 1 bp has a mass of 650 Da, the
slopes of the calibration curves (%DNA in tail/Gy) were used to calculate how
many lesions/10
6 bp a particular percentage of DNA in the tail corresponded to:
%DNA in tailsample
slope of calibration curve
 
0:29
109   650   1065 number of lesions=10
6 bp:
In order to get the number of lesions/10
6 Guanines (Gua), the number of
lesions/10
6 bp is multiplied by 0.44. The slope of the calibration curve refers to
Table I. Comet assay conditions used by the 10 different laboratories
Laboratory LMP agarose
(% in PBS)
Enzyme
incubation
(min)
Electrophoresis Alkali
(min)
Stain Software
Time
(min)
Voltage
(V)
V/cm
a Current
(mA)
1 0.75 45 20 30 0.9 300 40 YOYO-1 Comet IV (Perceptive Instruments)
2 0.75 30 30 24 1.5 300 40 EtBr Komet 4.0 (Kinetic Imaging Ltd)
3 0.65 10 20 25 0.9 300 20 EtBr Comet III (Perceptive Instruments)
4 0.65 25 24 22 1.5 300 20 EtBr Comet IV (Perceptive Instruments)
5 0.75 45 20 25 1.1 300 40 YOYO-1 —
6 0.6 30 20 30 0.9 300 20 PI Komet 5.5 (Kinetic Imaging Ltd)
7 1 30 30 25 1.6 260–300 40 DAPI Comet IV (Perceptive Instruments)
81
b 45 20 25 1.1 300 40 EtBr Cometa 1.5 (Immagini e Computer, Italy)
9 1 30 30 25 0.8 300 20 DAPI LUCIA 4.61 (Precoptic C, Czech Republic)
10 0.8 30 20 23 1.2 300 40 EtBr Komet 5.5 (Kinetic Imaging Ltd)
The dyes used are 4,6#-diamidino-2-phenylindole dihydrochloride (DAPI), ethidium bromide (EtBr), propidium iodide (PI) and YOYO-1 iodide (YOYO-1). All
laboratories used low-melting point (LMP) agarose.
aV/cm was calculated using a spreadsheet published on COMICS’ homepage (http://comics.vitamib.com/electrophoresis-physics). COMICS is an European Union
funded project which focuses on reﬁnement of the comet and DNA repair assays.
bThe agarose was diluted in TAE (buffer solution containing a mixture of Tris base, acetic acid and EDTA) instead of PBS.
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6   10
12 Da DNA, whereas A549 cells contain 12   10
12 Da DNA. However,
we assume that the %DNA in tail in the standard curve samples would not have
been affected if another cell line with a different amount of DNA had been
used.
Statistics
Statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL,
USA). The statistical analyses were carried out by parametric tests using
general linear models (GLM), correlation analyses, z-tests (Fisher’s z trans-
formation) and Levene’s tests. In the GLM analyses, the level of DNA lesions
was the dependent variable, the laboratory was a random variable and the rest
of the variables, i.e. concentration of photosensitizer, duration of alkaline treat-
ment, duration of electrophoresis, duration of enzyme treatment and agarose
density, were covariate (continuous) variables. Assessment of the contribution
of each variable to the overall variation was calculated from the sum of squares
in the statistical analysis. In Levene’s test, the homogeneities of variances were
tested between data transformed with the laboratory-speciﬁc calibration curves
and data transformed by a mutual standard curve (the mean of the laboratory-
speciﬁc calibration curves). Throughout this study, P values , 0.05 were
considered as indicating statistical signiﬁcance. The statistical analyses are
based on data both from %DNA in tail and by visual score.
Results
First, we describe the measurement of calibration samples, i.e.
cells c-ray irradiated with different doses, in the different lab-
oratories; the results give a picture of inter-laboratory variation
in assaying simple DNA breaks. ‘DNA breaks’ includes DNA
SSB and ALS. Next, we give the results obtained with coded
samples, ﬁrst looking at simple DNA breaks. The coded sam-
ples contained different amounts of 8-oxoguanine, which were
converted to strand breaks with FPG; thus, the breaks measured
include DNA breaks and 8-oxoguanine. By subtracting the
level of DNA breaks, we obtain net FPG-sensitive sites, i.e.
8-oxoguanine; this is obviously possible only for the eight
laboratories that measured DNA breaks. The data are analysed
as ‘raw’ values (%DNA in tail) and then converted to lesions/
10
6 bp using the calibration curve for each laboratory.
DNA breaks in calibration curve samples
The mean level of DNA breaks (i.e. SSB and ALS) in the cal-
ibration curve samples measured as (or converted to) %DNA in
tail by 10 different laboratories using their own comet assay
protocols are presented in Figure 1. The level of DNA breaks
measured as both %DNA in tail (n 5 10) and tail moment
(n 5 7) are presented as mean   SD in Table II. There were
very large variations in levels of DNA breaks reported by the
different laboratories, which is probably explained by differ-
ences in the comet assay protocols. The dose of ionizing
radiation, inter-laboratory variation and unexplained variation
contributed to 59, 28 and 13%, respectively, of the total var-
iation (GLM analysis). Both the dose of ionizing radiation and
the inter-laboratory variation contributed signiﬁcantly (P
, 0.001) to the level of DNA breaks expressed as %DNA in
tail. All laboratories reported signiﬁcant linear dose–response
relationships (R
2
mean 5 0.970, range: 0.931–0.995).
DNA breaks in the coded samples
The level of DNA breaks in the coded samples measured as
%DNA in tail (n 5 8), tail moment (n 5 6) and lesions/10
6 bp
(n 5 8) are presented as mean   SD in Table III. As can be
seen, there is a dose-dependent increase for both the %DNA in
tail as well as the number of lesions/10
6 bp. In fact, seven of
eight laboratories reported a positive ranking of DNA breaks
with concentration of photosensitizer in the three coded
samples. The concentration of photosensitizer, inter-laboratory
variation and unexplained variation contributed 7, 87 and 6%,
respectively, to the total variation of DNA breaks expressed as
%DNA in tail (GLM analysis). Such a low contribution of the
concentration was expected since the photosensitizer induces
mainly oxidative damage to DNA and not DNA breaks. None-
theless, both the contribution of the concentration of photosen-
sitizer and the inter-laboratory variation to the total variation of
%DNA in tail was statistically signiﬁcant (P , 0.001). The
mean of the linear dose–response relationships reported by the
laboratories was R
2
mean 5 0.83 (range: 0.09–1.00). When
transforming the %DNA in tail to lesions/10
6 bp using the
laboratory-speciﬁc calibration curves, the Pearson correlation
coefﬁcient r increased from 0.27 to 0.36 (correlation between
the level of DNA breaks and concentration of photosensitizer).
The concentration of photosensitizer, inter-laboratory variation
and unexplained variation contributed 13, 79 and 9%, respec-
tively, of the total variation of DNA breaks expressed as
lesions/10
6 bp (GLM analysis).
DNA breaks and FPG-sensitive sites in the coded samples
The results from FPG treatment (i.e. the sum of DNA breaks
and FPG-sensitive sites) expressed as %DNA in tail and
lesions/10
6 bp (n 5 10) in the three coded samples are shown
in Figure 2A and B, respectively. Nine of 10 laboratories
reported a positive ranking of the FPG-treated samples with
concentration of photosensitizer in the coded samples (Figure 2).
The mean of the linear dose–response relationships for the sum
Table II. DNA breaks
a in calibration curve samples consisting of THP1 cells
exposed to 0, 2.5, 5 and 10 Gy, respectively, measured with the comet assay
by 10 different laboratories using their own protocols
Dose (Gy) %DNA in tail, n 5 10 Tail moment, n 5 7
Mean (SD) CV (%) Mean (SD) CV (%)
0 5.5 (5.4) 99 1.3 (2.0) 147
2.5 21.8 (11.3) 52 6.2 (4.8) 78
5 37.3 (19.3) 52 13.4 (10.3) 76
10 60.0 (25.9) 43 29.9 (20.7) 69
Some laboratories have reported data with more than one end point.
ai.e. SSB and ALS.
Fig. 1. The levels of DNA breaks in calibration curve samples of THP1 cells
exposed to 0, 2.5, 5 or 10 Gy. Ten laboratories used their own comet assay
protocols to measure the levels of DNA breaks. The levels of DNA breaks are
presented as mean values of % DNA in tail (n 5 10, R
2 5 0.594, P , 0.001).
Inter-laboratory variation in oxidative damage to DNA
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2
mean 5 0.94
(range: 0.76–1.00). The dose–response was highly signiﬁcant
both for data reported as %DNA in tail and after conversion to
lesions/10
6 bp using the laboratory-speciﬁc calibration curves
(P , 0.001). The Pearson correlation coefﬁcient was increased
from r 5 0.64 to r 5 0.80 after conversion to lesions/10
6 bp.
However, this increase of the Pearson correlation coefﬁcient
was not statistically signiﬁcant (z-test, P . 0.05). The sum of
DNA breaks and FPG-sensitive sites measured as %DNA in
tail (n 5 10), tail moment (n 5 7) and lesions/10
6 bp (n 5 10)
are presented as mean   SD in Table III. The coefﬁcient of
variation in the sum of DNA breaks and FPG-sensitive sites
between the participating laboratories was lower for all con-
centrations after converting the end point %DNA in tail to
lesions/10
6 bp using the laboratory-speciﬁc calibration curves
(Table III). However, this decreased variation between lab-
oratories was only signiﬁcant for 0.8-lM photosensitizer Ro
19-8022 (P , 0.05, Levene’s test).
Both the concentration of photosensitizer (P , 0.001, positive
association) and the inter-laboratory variation (P , 0.001)
contributed signiﬁcantly to the total variation of the sum of
DNA breaks and FPG-sensitive sites expressed as %DNA in tail
(GLM analysis, Table IV). In a multiple regression analysis of
the concentration of photosensitizer and the different protocol
steps, the contribution to the variation of the concentration of
photosensitizer (P , 0.001, positive association) and the density
of agarose gels (P , 0.001, negative association) were highly
signiﬁcant and the contribution of the duration of alkaline
treatment (P , 0.01, positive association), duration of electro-
phoresis (P , 0.01, positive association) and duration of
enzyme treatment (P , 0.05, positive association) were sig-
niﬁcant (GLM analysis, Table IV). By converting the %DNA in
tail to lesions/10
6 bp, the contribution of the concentration of
photosensitizer was increased from 41 to 64% (GLM analysis,
Tables IV and V). In a multiple regression analysis of the
concentration of photosensitizer and the different protocol steps,
the contribution of the concentration of photosensitizer remained
highly signiﬁcant (P , 0.001, positive association). The dura-
tion of electrophoresis (P , 0.001, positive association) and
agarose density (P , 0.01, negative association) also contrib-
uted signiﬁcantly to the variation in the sum of DNA breaks and
FPG-sensitive sites expressed as lesions/10
6 bp (Table V).
Table III. DNA lesions in coded samples consisting of A549 cells exposed to 0, 0.2 and 0.8 lM photosensitizer Ro 19-8022 and light, respectively, measured with
the comet assay
Photosensitizer (lM) %DNA in tail Tail moment Lesions/10
6 bp
Mean (SD) CV (%) Mean (SD) CV (%) Mean (SD) CV (%)
DNA breaks
a,
b
0 7.1 (5.6) 78 2.1 (2.3) 108 0.27 (0.16) 59
0.2 8.4 (6.1) 73 2.6 (2.9) 111 0.33 (0.19) 59
0.8 11.2 (8.1) 72 3.6 (3.3) 90 0.46 (0.29) 62
DNA breaks
a and FPG-sensitive sites
c
0 14.3 (7.8) 54 4.4 (3.4) 78 0.49 (0.19) 38
0.2 27.2 (15.8) 58 9.7 (7.3) 75 0.96 (0.36) 38
0.8 50.7 (27.9) 55 27.2 (17.7) 65 1.75 (0.55) 32
Net FPG-sensitive sites
b
0 6.1 (4.2) 68 2.1 (2.2) 101 0.20 (0.13) 64
0.2 19.2 (13.3) 69 6.8 (6.0) 87 0.69 (0.28) 40
0.8 40.5 (22.6) 56 22.9 (16.5) 72 1.41 (0.43) 31
Lesions/10
6 bp have been calculated by using the laboratory-speciﬁc calibration curves. Some laboratories have reported data with more than one end point.
ai.e. SSB and ALS.
bEnd points presented are %DNA in tail (n 5 8), tail moment (n 5 6) and lesions/10
6 bp (n 5 8).
cEnd points presented are %DNA in tail (n 5 10), tail moment (n 5 7) and lesions/10
6 bp (n 5 10).
Fig. 2. The sum of DNA breaks and FPG-sensitive sites in coded samples
with A549 cells exposed to light and 0, 0.2 or 0.8 lM of photosensitizer Ro
19-8022 in PBS. Ten laboratories used their own comet assay protocols to
measure the sum of DNA breaks and FPG-sensitive sites. Data are
presented as (A) %DNA in tail and as (B)l e s i o n s / 1 0
6 bp. The amount of
lesions/10
6 bp has been calculated based on the assumption that 1 Gy
induces 0.29 strand breaks/10
9 Da DNA and using laboratory-speciﬁc
calibration curves.
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plained fraction of the variation) was higher in models with
DNA lesions as dependent variable and only the concentration
of photosensitizer as independent variable than in multiple
regression models that also contained either laboratory or dif-
ferent protocol steps as independent variables (Tables IV and
V). The model with the concentration of photosensitizer and
laboratory as independent variables had a lower unexplained
fraction of the variation compared with models with speciﬁc
protocol differences (Tables IV and V).
Net FPG-sensitive sites in the coded samples
The levels of net FPG-sensitive sites expressed as %DNA in
tail and lesions/10
6 bp (n 5 8) in the three coded samples are
shown in Figure 3A and B, respectively. Seven of eight
laboratories reported a positive ranking of net FPG-sensitive
sites with concentration of photosensitizer in the coded
samples. The mean of the linear dose–response relationships
was R
2
mean 5 0.90 (range: 0.45–1.00). The dose–response
relationship was highly signiﬁcant both for data reported as
%DNA in tail and after conversion to lesions/10
6 bp using
the laboratory-speciﬁc calibration curves (P , 0.001). The
Table IV. Contribution of the concentration of photosensitizer Ro 19-8022,
analyzing laboratory and protocol steps to the variation of the sum of DNA
breaks and FPG-sensitive sites expressed as %DNA in tail
Variable R
2
model % of total variation SDres
Concentration Variable Residual
Concentration 0.406 41*** — 59 18.5
Concentration þ
laboratory
a
0.845 41*** 44*** 16 9.4
Concentration
b 0.761 38*** 22 11.7
Alkaline treatment
(min)
b
8**
Electrophoresis
(min)
b
9**
Enzyme treatment
(min)
b
6*
Agarose density
b 17***
Concentration þ
alkaline treatment
(min)
c
0.566 41*** 16** 43 15.8
Concentration þ
electrophoresis
(min)
c
0.410 41*** 0
ns 59 18.4
Concentration þ
enzyme treatment
(min)
c
0.520 41*** 11* 48 16.6
Concentration þ
agarose density
c
0.415 41*** 1
ns 59 18.3
*P , 0.05, **P , 0.01 and ***P , 0.001.
aConcentration and laboratory in one model.
bConcentration and different protocol steps together in one model.
cConcentration and one protocol step at a time in a model.
Table V. Contribution of the concentration of photosensitizer Ro 19-8022,
analyzing laboratory and protocol steps to the variation of the sum of DNA
breaks and FPG-sensitive sites after conversion to lesions/106 bp using the
laboratory-speciﬁc calibration curves (n 5 10)
Variable R
2
model % of total variation SDres
Concentration Variable Residual
Concentration 0.643 64*** — 36 0.39
Concentration
þ laboratory
a
0.878 64*** 24** 12 0.23
Concentration
b 0.856 60*** 13 0.25
Alkaline treatment
(min)
b
1
ns
Electrophoresis
(min)
b
18***
Enzyme treatment
(min)
b
2
ns
Agarose density
b 6**
Concentration þ
alkaline treatment
(min)
c
0.667 64*** 2
ns 33 0.38
Concentration þ
electrophoresis
(min)
c
0.761 64*** 12** 24 0.32
Concentration þ
enzyme treatment
(min)
c
0.652 64*** 1
ns 35 0.38
Concentration þ
agarose density
c
0.646 64*** 0
ns 35 0.39
*P , 0.05, **P , 0.01 and ***P , 0.001.
aConcentration and laboratory in one model.
bConcentration and different protocol steps together in one model.
cConcentration and one protocol step at a time in a model.
Fig. 3. The level of net FPG-sensitive sites (the sum of DNA breaks and FPG-
sensitive sites minus the level of DNA breaks) in coded samples with A549
cells exposed to light and 0, 0.2 or 0.8 lM of photosensitizer Ro 19-8022 in
PBS. Eight laboratories used their own comet assay protocols to measure the
net FPG-sensitive sites. Data are presented as (A) %DNA in tail and as (B)
lesions/10
6 bp. The fraction of explained variation strongly increased when
using lesions/10
6 bp as end point. The amount of lesions/10
6 bp was calculated
based on the assumption that 1 Gy induces 0.29 strand breaks/10
9 Da DNA
and using laboratory-speciﬁc calibration curves.
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to r 5 0.85 after conversion to lesions/10
6 bp. This increase
of the Pearson correlation coefﬁcient was not statistically
signiﬁcant (z-test, P . 0.05). The amount of net FPG-sensitive
sites in the coded samples measured as %DNA in tail (n 5 8),
tail moment (n 5 6) and the amounts of lesions/10
6 bp (n 5 8)
are presented as mean   SD in Table III. These values
correspond to 0.09, 0.30 and 0.62 net FPG-sensitive sites/10
6
Gua for the concentrations 0, 0.2 and 0.8 lM photosensitizer,
respectively. The variation in the measured net FPG-sensitive
sites between the participating laboratories was lower for all
concentrations of the photosensitizer after converting the end
point %DNA in tail to lesions/10
6 bp (Table III). However, this
decrease was not statistically signiﬁcant (Levene’s test).
Both the concentration of photosensitizer (P , 0.001, posi-
tive association) and the inter-laboratory variation (P , 0.01)
contributed signiﬁcantly to the total variation of net FPG-
sensitive sites expressed as %DNA in tail (GLM analysis,
Table VI). In a multiple regression analysis of the concentra-
tion of photosensitizer and the different protocol steps, it was
found that the concentration of the photosensitizer explained
54% (P , 0.001, positive association) of the variation when
using the end point %DNA in tail. In addition, the contribu-
tions of the duration of alkaline treatment (P , 0.01, positive
association) and agarose density (P , 0.05, negative associ-
ation) were signiﬁcant (Table VI). After conversion to the end
point lesions/10
6 bp, the contribution of the concentration of
photosensitizer was improved from 49 to 73% (GLM analysis
of concentration of photosensitizer and laboratory, Tables VI
and VII). In a multiple regression analysis of the concentration
of the photosensitizer and the protocol steps, the contributions
of the concentration of photosensitizer (P , 0.001, positive as-
sociation), duration of alkaline treatment (P , 0.05, positive
association), duration of electrophoresis (P , 0.05, positive as-
sociation) and agarose density (P , 0.05, negative association)
were signiﬁcant (Table VII).
As in the case of the sum of FPG-sensitive sites and DNA
breaks, the residual variation was higher in models with net
FPG-sensitive sites as dependent variable and only the con-
centration of photosensitizer as independent variable than in
multiple regression models that also contained either laboratory
or different protocol steps as independent variables (Tables VI
and VII). The model with the concentration of photosensitizer
and laboratory as independent variables had a lower unex-
plained fraction of the variation compared to models with
speciﬁc protocol differences (Tables VI and VII).
Discussion
The laboratories in this ECVAG study were successful in
ﬁnding a dose–response relationship of FPG-sensitive sites,
where nine of 10 participating laboratories identiﬁed the dose–
response for the sum of DNA breaks and FPG-sensitive sites.
Regarding net FPG-sensitive sites, seven of eight laboratories
identiﬁed this dose–response. In a similar trial conducted by
European Standards Committee on Oxidative DNA damage
(ESCODD) published in 2003, only three of eight laboratories
could detect the dose–response relationship in net FPG-
sensitive sites using the comet assay (14). In the ESCODD
trial, human transformed epithelial (HeLa) cells were exposed
to 0, 0.2 or 0.4 lM photosensitizer Ro 19-8022 and light for 2
min, whereas in the present study, A549 cells were exposed to
Table VI. Contribution of the concentration of photosensitizer Ro 19-8022,
analyzing laboratory and protocol steps to the variation of the net FPG-
sensitive sites expressed as %DNA in tail
Variable R
2
model % of total variation SDres
Concentration Variable Residual
Concentration 0.485 49*** — 51 14.8
Concentration þ
laboratory
a
0.826 49*** 34** 17 8.6
Concentration
b 0.808 54*** 22 9.0
Alkaline treatment
(min)
b
16**
Electrophoresis
(min)
b
1
ns
Enzyme treatment
(min)
b
0
ns
Agarose density
b 6*
Concentration þ
alkaline treatment
(min)
c
0.747 49*** 26*** 25 10.4
Concentration þ
electrophoresis
(min)
c
0.485 49*** 0
ns 51 14.8
Concentration þ
enzyme treatment
(min)
c
0.595 49*** 11* 40 13.1
Concentration þ
agarose density
c
0.487 49*** 0
ns 51 14.8
*P , 0.05, **P , 0.01 and ***P , 0.001.
aConcentration and laboratory in one model.
bConcentration and different protocol steps together in one model.
cConcentration and one protocol step at a time in a model.
Table VII. Contribution of the concentration of photosensitizer Ro 19-8022,
analyzing laboratory and protocol steps to the variation of the net FPG-
sensitive sites after conversion to lesions/106 bp using the laboratory-speciﬁc
standard curves (n 5 8)
Variable R
2
model % of total variation SDres
Concentration Variable Residual
Concentration 0.727 73*** — 27 0.31
Concentration þ
laboratory
a
0.878 73*** 15
ns,b 12 0.20
Concentration
c 0.864 72*** 13 0.22
Alkaline treatment
(min)
c
4*
Electrophoresis
(min)
c
5*
Enzyme treatment
(min)
c
0
ns
Agarose density
c 5*
Concentration þ
alkaline treatment
(min)
d
0.778 73*** 5* 22 0.28
Concentration þ
electrophoresis
(min)
d
0.756 73*** 3
ns 24 0.29
Concentration þ
enzyme treatment
(min)
d
0.729 73*** 0
ns 27 0.30
Concentration þ
agarose density
d
0.729 73*** 0
ns 27 0.30
*P , 0.05, **P , 0.01 and ***P , 0.001.
aConcentration and laboratory in one model.
bBorderline signiﬁcance (P 5 0.052).
cConcentration and different protocol steps together in one model.
dConcentration and one protocol step at a time in a model.
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1300, 0.2 or 0.8 lM Ro 19-8022 and light for 5 min. The narrower
concentration range used in the ESCODD trial might in part
explain why the present study was more successful at detecting
the dose–response.
Any comet assay end point can be expressed as lesions/10
6
bp, as lesions/10
9 Da DNA, as lesions/cell or as FPG-
sensitive sites/10
6 Gua by calibration with ionizing radiation.
In the present study, the slopes of the laboratory-speciﬁc
calibration curves were used to calculate how many lesions/
10
6 bp particular amounts of DNA lesions expressed as
%DNA in tail corresponded to. The difference between the 10
laboratories was reduced (Figures 2 and 3), after the level of
DNA lesions expressed as %DNA in tail had been converted
to lesions/10
6 bp. By converting %DNA in tail to lesions/10
6
bp, the coefﬁcient of variation was decreased for all doses,
although statistical signiﬁcance was not reached for all tests
(Table III). The increased values of Pearson’s correlation
coefﬁcients after conversion to lesions/10
6 bp for both sum of
D N Ab r e a k sa n dF P G - s e n s i t i v es i t e s( f r o mr 5 0.64 to
r 5 0.80) and net FPG-sensitive sites (from r 5 0.70 to
r 5 0.85) underscore the ability of laboratory-speciﬁc
calibration curves to reduce the inter-laboratory variation
although these increases were not statistically signiﬁcant. It
should be kept in mind that transformation of primary comet
assay end points using calibration curves or reference
standards is associated with a variation that is equal to the
sum of the variations in the sample and calibration sample.
Therefore, even though the reduction of variation was not
signiﬁcant, it should be underlined that such a reduction is
relevant since it managed to cope with the variation
introduced by the transformation and reduce the overall
variation. It is reasonable to assume that inter-laboratory
differences in protocols were responsible for a large part of
the variation. When analyzing how much of the variation in
net FPG-sensitive sites was caused by the concentration of the
photosensitizer and the analyzing laboratory, it was found that
the contribution of the concentration of the photosensitizer
was increased from 49 to 73% by converting %DNA in tail to
lesions/10
6 bp (Tables VI and VII). Similar analyses for DNA
breaks were not made since the Ro 19-8022 plus light mainly
induces oxidatively damaged DNA and not DNA breaks. The
decrease of the inter-laboratory variation after the conversion
to lesions/10
6 bp observed in the present study indicates that
such a conversion would facilitate comparisons between data
from different research groups by decreasing the inﬂuence of
the differences in used protocols. Forchhammer et al. (9) have
shown previously that it is possible to reduce the variation in
DNA lesions caused by using different comet assay protocols
by using protocol-speciﬁc calibration curves. Use of lesions/
10
6 bp, lesions/10
9 Da DNA, lesions/cell or FPG-sensitive
sites/10
6 Gua as end points instead of other end points (e.g.
%DNA in tail and arbitrary units from visual scoring) also has
other advantages. The amount of lesions/10
6 bp would be
easier to understand for individuals who are not familiar with
the comet assay compared to end points such as %DNA in
tail, tail moment, arbitrary units, tail length and different types
of comet distribution. Furthermore, if scientists could agree
on one end point it would facilitate comparisons between
different studies and laboratories. The amount of lesions/10
6
bp can be calculated regardless of whether visual or
computerized comet scoring is used. Conversion to lesions/
10
6 bp does, however, require calibration with ionizing
radiation. A second option would be to introduce an authentic
internal standard. An authentic internal standard consisting of
‘reference’ cells (which generate reference-comets that can be
readily distinguished from test comets present in the same gel)
can be used to reduce intra- and inter-experiment variability in
measures of DNA damage formation and repair (15).
The 10 participating laboratories in this validation trial used
different protocols, but the solutions used were either very
similar (lysis solution) or identical (enzyme and alkaline/
electrophoresis solutions). The agarose densities used varied
between 0.65 and 2% agarose, the duration of the alkaline
treatment varied between 20 and 40 min, the duration of the
electrophoresis varied between 20 and 30 min and the length
of the FPG treatment varied between 10 and 45 min (see
Materials and Methods and Table I). Forchhammer et al. (9)
previously showed that the duration of both alkaline treatment
(20 and 30 min) and electrophoresis (20 and 40 min)
signiﬁcantly affected the level of oxidatively damaged DNA
detected by visual scoring. It should be emphasized that
the present study was not designed to investigate the poten-
tial inﬂuence of differences in protocols, and the degrees
of freedom and number of participating laboratories are
not optimal for such analyses. However, in the present study,
statistical models with laboratory as categorical variable
explained more of the variation than models with speciﬁc
steps in the comet assay protocols (Tables IV–VII). In
statistical models with only the concentration of the photosen-
sitizer as independent variable, the residual variation (the
unexplained fraction of the variation) was larger than in all
models with either laboratory or different protocol steps as
independent variables (Tables IV–VII). This indicates that the
inter-laboratory variation in DNA damage to a large extent is
explained by the variation in protocols but that it is difﬁcult to
point out any critical step in the protocol. It is possible that
differences in protocols not included in the statistical analyses
such as the use of different software systems also might
contribute to the inter-laboratory variation.
In conclusion, the participating laboratories were successful
in ﬁnding a dose–response relationship of oxidatively damaged
DNA where nine of 10 laboratories reported the same ranking
of the FPG treatment and seven of eight laboratories reported
the same ranking of net FPG-sensitive sites in the coded sam-
ples. The inter-laboratory variation in assessment of oxida-
tively damaged DNA was largely due to differences in the
protocols. The statistical analyses imply that it is assay pro-
tocols rather than single steps in the procedure that give rise to
the inter-laboratory variation. After conversion of the data to
lesions/10
6 bp using laboratory-speciﬁc calibration curves, the
variation between the laboratories was reduced for all con-
centrations of photosensitizer Ro 19-8022. In addition, the
contribution of the concentration of Ro 19-8022 to the varia-
tion in net FPG-sensitive sites was increased from 49 to 73%
by conversion from %DNA in tail to lesions/10
6 bp using the
laboratory-speciﬁc calibration curves. We plan to repeat the
present study with standardized protocols to enable compar-
isons between laboratories without the inﬂuence of protocol
differences.
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